Immunotherapy by allogeneic lymphocytes and cytokines following autologous and allogeneic bone marrow stem cell transplantation

S. Slavin, E. Naparstek, A. Nagler, A. Ackerstein, G. Varadi, J. Kapelushnik, R. Or

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

This chapter presents several alternative therapeutic approaches based on passive adoptive transfer of immunocompetent donor allogeneic bone marrow or peripheral blood lymphocytes (PBL) or in vitro activated allogeneic PBL, with or without further in vivo activation of effector cells with recombinant human interleukin 2. The role of allogeneic cell-therapy in conjunction with BMT is best documented by comparing the rate of relapse of patients undergoing syngeneic and autologous BMT in comparison with allogeneic BMT, both being conditioned by identical myeloablative protocols. After induction of stable chimerism recipients are expected to accept donor lymphocytes and permit induction of effective graft vs-leukemia. The use of adoptive allogeneic cell therapy for the treatment of cancer represents the beginning of a new era in applying biological therapy of cancer. In the future, tumor-selective effector cells may be obtained by choosing well-defined T cell subsets, with possible further in vitro expansion and activation of anti-cancer effector cells.

Original languageEnglish
Title of host publicationAutologous Stem Cell Transplantation
Subtitle of host publicationBiological and Clinical Results in Malignancies
PublisherTaylor and Francis
Pages431-439
Number of pages9
ISBN (Electronic)9781000102826
DOIs
StatePublished - 1 Jan 2020
Externally publishedYes

Fingerprint

Dive into the research topics of 'Immunotherapy by allogeneic lymphocytes and cytokines following autologous and allogeneic bone marrow stem cell transplantation'. Together they form a unique fingerprint.

Cite this